Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
John Crabb, PhD, joined Cleveland Clinic in 1998 as a full Staff member in the Department of Ophthalmic Research, Cole Eye Institute, with a secondary appointment in the Department of Cell Biology, Lerner Research Institute. He is a full Faculty member and Professor in the Department of Chemistry, Case Western Reserve University, and in the Departments of Ophthalmology and Molecular Medicine in the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He holds adjunct professorships in the Department of Chemistry, Cleveland State University, and the School of Biomedical Sciences, Kent State University.
A major focus of Dr. Crabb's research concerns age-related macular degeneration (AMD). Proteomic biomarker studies are directed toward developing a blood test for AMD to identify those at risk, before there is clinical evidence of the disease. Other proteomic studies in his laboratory focus on glaucoma biomarker discovery and the molecular details of the retinoid visual cycle. Information about the laboratory can be found online at www.lerner.ccf.erg/eye/crabb/.
Dr. Crabb received a Bachelor's Degree in biology and chemistry from Lewis & Clark College in Portland, Ore., and a doctorate in microbiology from the University of Kansas Medical Center, Kansas City, Kan. He pursued postdoctoral training in biological chemistry at the University of Michigan and in the biochemistry of vision at the University of Washington. Prior to joining the Cole Eye Institute, he was a Senior Scientist and Director of Protein Chemistry at the Adirondack Biomedical Research Institute in Lake Placid, N.Y. During the 14 years he was in upstate New York, Dr. Crabb maintained adjunct faculty appointments at the University of Vermont, Clarkson University and Albany Medical College. Prior to New York, he was an Assistant Professor and Director of the Protein Sequencing Facility in the Institute of Physiological Chemistry, Ruhr University, Bochum, Germany.
Dr. Crabb has served full 5-year terms on NSF and NIH grant review panels and is a member of the editorial boards of Experimental Eye Research and the Journal of Ocular Biology, Disease and Informatics. He has published more than 190 basic-science research articles and currently has research support from government, private and corporate sources.
age-related macular degeneration
primary open angle glaucoma
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 9/17/2013, Dr. Crabb has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Royalty Payments. Dr. Crabb receives or has the right to receive royalty payments for inventions or discoveries commercialized through the companies shown below:
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.